SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.

NDAQ:SCYX - Post by User

SCYNEXIS Inc

<< Previous

Bullboard Posts

Next >>

(31)
•••

Comment by dmacdon Apr 22, 2022 4:48pm

80 Views

Post# 34625156

RE:RE:RE:BREXAFEMME - published User side effects

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend. Probably trading at 70% current cash with an approved blockbuster drug in sales mode. New cash is either due to slow sales ramp or accelerated new programs. Management does not care about the SP which means retail will get fleeced more but I am hopeful this might be the end of the incompetent financings. Heads do need to roll here. Mario cannot remain on charge of the business side, and if he expects to then he owes shareholders an explanation, and why do some shareholders get treated differently than others. SEC should investigate Mario since clearly information is being shared with a selective audience.

<< Previous

Bullboard Posts

Next >>

Unlocking oil and gas opportunities globally and in the WCSB